(Q35753472)

10 August 2017

1 reference

title

Recent developments in the pharmacological treatment of Crohn's disease (English)

1 reference

10 August 2017

0 references

1

Radhika Srinivasan

1 reference

10 August 2017

Gary R Lichtenstein

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

published in

1 reference

10 August 2017

volume

13

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

373-391

1 reference

A simple index of Crohn's-disease activity

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

TNF inhibition as therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Interleukin-10-deficient mice develop chronic enterocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.373

10.1517/13543784.13.4.373

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference